Development of a synthetic cyclized peptide derived from alpha-fetoprotein that prevents the growth of human breast cancer.
The peptide, EMTPVNPG, derived from alpha-fetoprotein, inhibits estrogen-stimulated growth of immature mouse uterus and estrogen-dependent proliferation of human breast cancer cells. However, the biological activities of the peptide diminish over time in storage, even when in the lyophilized state, probably because of peptide aggregation through hydrophobic interaction among monomers. Two analogs of EMTPVNPG were designed with the intent of minimizing aggregation and retaining biological activity during prolonged storage. EMTOVNOG, where O is 4-hydroxyproline, is a linear peptide generated by substituting 4-hydroxyproline for the two prolines, thereby increasing peptide hydrophilicity. This analog exhibited a dose-dependent inhibition of estrogen-stimulated growth of immature mouse uterus similar to that of EMTPVNPG (maximal activity at 1 microg/mouse). A second analog, cyclo-(EMTOVNOGQ), a hydrophilic, cyclic analog with increased conformational constraint, was as potent as the other peptides in its inhibition of estrogen-dependent growth of immature mouse uterus, and had an expanded effective dose range. Both linear and cyclized hydroxyproline-substituted analogs exhibited indefinite shelf-life. Furthermore, both analogs inhibited the estrogen-dependent growth of MCF-7 human breast cancer growing as a xenograft in SCID mice. These analogs may become significant, novel agents for the treatment of breast cancer.
Mesfin
F B
FB
Center for Immunology and Microbial Diseases, Albany Medical College, Albany 12208, USA.
Andersen
T T
TT
Jacobson
H I
HI
Zhu
S
S
Bennett
J A
JA
D019943:Amino Acid Substitution; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000139:chemically induced / Q000517:prevention & control*; D002455:Cell Division / Q000187:drug effects; D015195:Drug Design; D004967:Estrogens / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D008968:Molecular Conformation; D010456:Peptides, Cyclic / Q000138:chemical synthesis* / Q000494:pharmacology*; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors*; D014599:Uterus / Q000187:drug effects* / Q000254:growth & development; D023041:Xenograft Model Antitumor Assays; D000509:alpha-Fetoproteins / Q000737:chemistry
D000970:Antineoplastic Agents; C440749:EMTPVNPG peptide; D004967:Estrogens; D010456:Peptides, Cyclic; C440750:QMTPVNPG peptide; D011960:Receptors, Estrogen; D000509:alpha-Fetoproteins